Beam Therapeutics (BEAM) Net Cash Flow (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Net Cash Flow data on file, last reported at -$6.6 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 102.72% year-over-year to -$6.6 million in Q1 2026; TTM through Mar 2026 was -$239.5 million, a 199.72% decrease from a year earlier, with the FY2025 full-year figure at $11.5 million, up 107.45% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$6.6 million, down from $27.0 million in the prior quarter.
• Over the last five years, Net Cash Flow for BEAM reached as high as $266.9 million in Q4 2023 and fell as low as -$263.2 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$16.3 million across 5 years, with a median of -$14.1 million in 2025.
• On a YoY basis, Net Cash Flow climbed as much as 262.6% in 2025 and fell as far as 5422.76% in 2025.
• Year by year, Net Cash Flow stood at $76.3 million in 2022, then jumped by 249.97% to $266.9 million in 2023, then sank by 80.01% to $53.4 million in 2024, then sank by 49.39% to $27.0 million in 2025, then sank by 124.57% to -$6.6 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$6.6 million in Q1 2026, $27.0 million in Q4 2025, and -$14.1 million in Q3 2025.